Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
NuCana NASDAQ NCNA
$4.00 0.0000 0.0000%
Today share price
UK
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 18 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

210.68M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
193.66M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.77
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
52.67M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
1,252.27 %
Upcoming events NuCana All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart NuCana

Stock analysis NuCana

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-6.03 13.17
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
14.15 3.74
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-4.79 9.25
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.42 0.06
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-234.86 9.43

Price change NuCana per year

1.88$ 7.77$
Min Max

Summary analysis NuCana

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure NuCana

Revenue and net income NuCana

All parameters
Stock news NuCana All news
12 May 2023 в 23:20

NuCana Receives Notices That ADSs Don't Satisfy Nasdaq Listing Requirements

12 May 2023 в 23:15

NuCana Receives Notices That ADSs Don't Satisfy Nasdaq Listing Requirements

3 March 2022 в 20:08

NuCana Shares Reach All-Time Low on Scuttled Study >NCNA

3 March 2022 в 20:08

NuCana Shares Reach All-Time Low on Scuttled Study >NCNA

3 March 2022 в 14:19

NuCana Shares Plummet Premarket on Acelarin Study Failure >NCNA

3 March 2022 в 14:19

NuCana Shares Plummet Premarket on Acelarin Study Failure >NCNA

30 September 2021 в 17:55

NuCana Shares Drop 12% After Wednesday Rise

30 September 2021 в 17:55

NuCana Shares Drop 12% After Wednesday Rise

30 September 2021 в 02:20

ADRs End Lower; NuCana, Iberdrola Among Companies Actively Traded

30 September 2021 в 02:20

ADRs End Lower; NuCana, Iberdrola Among Companies Actively Traded

29 September 2021 в 20:20

NuCana Shares Rise 18% on Fast Track Designation for Cancer Treatment

29 September 2021 в 20:20

NuCana Shares Rise 18% on Fast Track Designation for Cancer Treatment

29 September 2021 в 15:20

NuCana Gets FDA Fast Track Designation for Acelarin

29 September 2021 в 15:20

NuCana Gets FDA Fast Track Designation for Acelarin

About company NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Address:
3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT
Company name: NuCana
Issuer ticker: NCNA
ISIN: US67022C1062
Country: UK
Exchange: NASDAQ
Currency: $
IPO date: 2017-09-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.nucana.com

On which stock exchange are NuCana (NCNA) stocks traded?

NuCana (NCNA) stocks are traded on NASDAQ.

What is the ticker of NuCana stocks (NCNA)?

The stock ticker of NuCana’s stocks or in other words, the code is NCNA. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does NuCana (NCNA) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, NuCana (NCNA) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are NuCana (NCNA) stocks traded?

NuCana (NCNA) stocks are traded on the NASDAQ exchange in dollars.

What is the price of NuCana (NCNA) stocks today?

The current price of NuCana stocks on 30.04.2024 is 4 dollars. per share.

What is the dynamics of NuCana (NCNA) stocks from the beginning of the year?

NuCana (NCNA) quotes have increased by 1163.02% from the beginning of the year up to 4 dollars. per 1 stocks.

How much did NuCana (NCNA) stocks increase in апреле 2024?

This month NuCana (NCNA) quotes have increased by 1587.76% to 4 dollars. per share.

How much are NuCana (NCNA) stocks worth?

Today, on October, 30.04.2024 NuCana’s (NCNA) stocks cost 4 dollars..

What is the market capitalization of NuCana (NCNA)?

Capitalization is the market value of NuCana (NCNA) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 30.04.2024, the market capitalization of NuCana (NCNA) is estimated at about 210680000 dollars.